O
Oncolytics Biotech
Developing pelareorep, an IV delivered I-O virus, promoting an inflamed tumor: waking the immune system
About Oncolytics Biotech
Oncolytics Biotech Inc. is a biotechnology company focused on developing innovative cancer treatments. The company's core product, pelareorep, is a unique immunotherapy designed to awaken the immune system and unlock its antitumor potential. Unlike other immunotherapies that require direct injection into tumors, pelareorep is delivered intravenously and is systemically active, meaning it can target cancer cells throughout the body. This makes it a versatile treatment option for various types of cancer. Oncolytics Biotech serves patients with cancer, aiming to improve their quality of life by offering more time with family and for personal passions. The company operates in the biotechnology and healthcare markets, primarily targeting oncology. Its business model involves the development and commercialization of pelareorep, either as a standalone treatment or in combination with other therapies, to enhance its efficacy. Revenue is generated through partnerships, licensing agreements, and potential future sales of pelareorep.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1988
- Headquarters
- Calgary, Canada
- Listing
- IPO 2001
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 71.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Oct 2025 | $50M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Apr 2025 | $20M | — | Alumni Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | EBITDA | Margin | Profit | Margin | R&D |
|---|---|---|---|---|---|
| 2026 | −$27M | — | −$23M | — | $16M |
| 2025 | −$27M | — | −$23M | — | $16M |
| 2024 | −$27M | — | −$23M | — | $16M |
| 2023 | −$28M | — | — | $13M | |
| 2022 | −$21M | — | — | ||
| 2021 | −$19M | — | — | ||
| 2020 | −$20M | — | — |
Growth signals
Latest recorded traffic for Oncolytics Biotech is 6.4K monthly website visits, up 10.3% over the last three months. Oncolytics Biotech's team grew 9.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Alumni Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oncolytics Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oncolytics Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.